Inhibition of hepatocellular carcinoma by fulvestrant involves the estrogen receptor α and Wnt pathways in vitro and in patients.

@article{Wang2014InhibitionOH,
  title={Inhibition of hepatocellular carcinoma by fulvestrant involves the estrogen receptor α and Wnt pathways in vitro and in patients.},
  author={Cong-Jun Wang and De-Kai Guo and T You and Dong-Wei Shen and Chao Wang and Lin Tang and Jian hua Wang and Rong-Hua Xu and Hui Zhang},
  journal={Molecular medicine reports},
  year={2014},
  volume={10 6},
  pages={3125-31}
}
The aim of the present study was to investigate the effect of anti-estrogen treatment (fulvestrant) on the biological activity of hepatocellular carcinoma (HCC), involving the estrogen receptor α (ERα) and Wnt pathways, and to evaluate whether ERα and Wnt inhibitory factor-1 (WIF1) could be biomarkers for anti-estrogen clinical therapy. H22 and HepG2 cells were treated with 0.04 to 625 nM fulvestrant and the WST-8 method was used to assess the inhibition rate after 72 h. Furthermore, prolactin… CONTINUE READING